Pharvaris N.V.
PHVS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001830487
In the last 90 days, Pharvaris N.V. insiders filed 0 open-market purchases and 20 sales; 125 institutions reported holding it in 13F filings for Q2 2026, worth $2.23B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q2 2023
Institutional positions in Pharvaris N.V. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- 0 vs. Q1 2023
- Shares held
- 28.9M
- +7.13M (+32.7%) vs. Q1 2023
- Total value
- $441.6M
- +$267.7M (+153.9%) vs. Q1 2023
- New holders
- 2
- 9 more added
- Sold out
- 2
- 4 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHVS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 125 | $2.23B |
| Q1 2026 | 110 | $1.67B |
| Q4 2025 | 106 | $1.64B |
| Q3 2025 | 83 | $1.44B |
| Q2 2025 | 60 | $792.7M |
| Q1 2025 | 52 | $705.5M |
| Q4 2024 | 54 | $855.8M |
| Q3 2024 | 51 | $834.2M |
| Q2 2024 | 36 | $808.6M |
| Q1 2024 | 35 | $980.5M |
| Q4 2023 | 36 | $1.14B |
| Q3 2023 | 21 | $606.6M |
| Q2 2023 | 21 | $441.6M |
| Q1 2023 | 21 | $173.9M |
| Q4 2022 | 25 | $239.6M |
| Q3 2022 | 21 | $173.6M |
| Q2 2022 | 20 | $494.0M |
| Q1 2022 | 22 | $397.1M |
| Q4 2021 | 22 | $321.1M |
| Q3 2021 | 25 | $380.3M |
| Q2 2021 | 28 | $406.3M |
| Q1 2021 | 33 | $616.5M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Pharvaris N.V.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock Inc. | 156 | $2.36K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 151 | $2.37K | 0.00% | +151 | New |
| UBS Group AG | 1,300 | $19.7K | 0.00% | +878+208.1% | Added |
| Schonfeld Strategic Advisors LLC | 11,600 | $175.6K | 0.00% | +100+0.9% | Added |
| Geode Capital Management, LLC | 18,643 | $292.9K | 0.00% | 00.0% | Unchanged |
| Lynx1 Capital Management LP | 21,225 | $321.3K | 0.21% | −5,000−19.1% | Reduced |
| Foresite Capital Management V, LLC | 34,142 | $516.9K | 0.38% | 00.0% | Unchanged |
| Morgan Stanley | 45,332 | $686.3K | 0.00% | −3,653−7.5% | Reduced |
| Walleye Capital LLC | 70,326 | $1.10M | 0.02% | −39,619−36.0% | Reduced |
| Silverarc Capital Management, LLC | 200,000 | $3.03M | 1.02% | −359,387−64.2% | Reduced |
| Soleus Capital Management, L.P. | 391,900 | $5.93M | 0.66% | +55,000+16.3% | Added |
| 5AM Venture Management, LLC | 587,600 | $8.90M | 2.22% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 973,614 | $14.7M | 0.84% | +157,154+19.2% | Added |
| VR Adviser, LLC | 1,326,200 | $20.1M | 3.21% | +1,326,200 | New |
| Novo Holdings A/S | 1,329,325 | $20.1M | 1.56% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,231,923 | $50.8M | 0.21% | 00.0% | Unchanged |
| FMR LLC | 3,387,157 | $53.2M | 0.00% | +71,919+2.2% | Added |
| Foresite Capital Management IV, LLC | 3,743,450 | $56.7M | 27.86% | +496,524+15.3% | Added |
| venBio Partners LLC | 4,264,672 | $64.6M | 23.37% | +1,986,097+87.2% | Added |
| General Atlantic LLC | 4,406,252 | $66.7M | 1.05% | +1,986,097+82.1% | Added |
| Bain Capital Life Sciences Investors, LLC | 4,868,784 | $73.7M | 7.59% | +1,688,183+53.1% | Added |
| Sio Capital Management, LLC | 0 | $0 | 0.00% | −228,385−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −1−100.0% | Sold out |